Information on EC 3.4.15.1 - peptidyl-dipeptidase A

New: Word Map on EC 3.4.15.1
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Search Reference ID:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Bacteria, Eukaryota

EC NUMBER
COMMENTARY hide
3.4.15.1
-
RECOMMENDED NAME
GeneOntology No.
peptidyl-dipeptidase A
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
release of a C-terminal dipeptide, oligopeptide-/-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of angiotensin I to angiotensin II, with increase in vasoconstrictor activity, but no action on angiotensin II
show the reaction diagram
-
-
-
-
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
hydrolysis of peptide bond
-
-
exopeptidase, C-terminus, dipeptide
-
CAS REGISTRY NUMBER
COMMENTARY hide
9015-82-1
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
HL721
-
-
Manually annotated by BRENDA team
recombinantly expressed in Pichia pastoris
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
precursor
SwissProt
Manually annotated by BRENDA team
Swiss strain
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
WO24
-
-
Manually annotated by BRENDA team
WO24
-
-
Manually annotated by BRENDA team
Rattus norvegicus Sprague-Dawley
Sprague-Dawley
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
pv. citri
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
metabolism
-
ACE is involved in the renin-angiotensin-aldosterone system, overview
physiological function
additional information
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(7-methoxycoumarin-2-acetic acid)-Ala-Ser-Asp-Lys-(N3-(2,4-dinitrophenyl)-L-2,3-diaminopropyl) + H2O
?
show the reaction diagram
-
-
-
?
(7-methoxycoumarin-2-acetic acid)-Ser-Asp-Lys-(N3-(2,4-dinitrophenyl)-L-2,3-diaminopropyl) + H2O
?
show the reaction diagram
-
-
-
?
(7-methoxycoumarin-2-acetyl)-Tyr-Val-Ala-Asp-Ala-Phe-Lys-(2,4-dinitrophenyl)-OH + H2O
?
show the reaction diagram
-
-
-
-
?
(7-methoxycoumarin-4-yl)acetyl-Ala-Ser-Asp-Lys-N3-(2,4-dinitrophenyl)-L-diaminopropionionate + H2O
?
show the reaction diagram
-
-
-
-
?
1-dimethylaminonaphthalene-5-sulfonyl-Gly-Gly-Gly + H2O
1-dimethylaminonaphthalene-5-sulfonyl-Gly + Gly-Gly
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Ala-Ala-Leu-Ala-Gly-nitrobenzylamide + H2O
?
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Ala-Ala-Tyr-Leu-Ala-Gly-nitrobenzylamide + H2O
?
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Ala-Tyr-Leu-Ala-Gly-nitrobenzylamide + H2O
?
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-L-Phe-L-Arg-L-Lys-2,4-dinitrophenyl-L-Pro + H2O
?
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Val-Tyr-Leu-Ala-Gly-nitrobenzylamide + H2O
?
show the reaction diagram
-
-
-
-
?
2-furanacryloyl-1-Phe-Gly-Gly + H2O
?
show the reaction diagram
-
-
-
-
?
2-furanacryloyl-Phe-Gly-Gly + H2O
2-furanacryloyl-Phe + Gly-Gly
show the reaction diagram
2-furylacryloyl-Phe-Gly-Gly + H2O
2-furylacrylic acid + Phe-Gly-Gly
show the reaction diagram
-
-
-
?
3-hydroxybutyryl-Gly-Gly-Gly + H2O
3-hydroxybutyryl-Gly + Gly-Gly
show the reaction diagram
-
-
-
-
?
3-hydroxybutyrylglycyl-glycyl-glycine + H2O
3-hydroxybutyrate + glycyl-glycine
show the reaction diagram
-
synthetic substrate for use in an spectrophotometric assay of ACE inhibitory activity, method development involving automation of the measurement with immobilized aminoacylase and 3-hydroxybutyrate dehydrogenase, optimization, detailed overview. Application to the screening of ACE inhibitors
-
-
?
3-hydroxybutyrylglycyl-glycyl-glycine + H2O
3-hydroxybutyrylglycine + Gly-Gly
show the reaction diagram
-
-
-
-
?
7-amido-4-carboxymethylcoumarin-APK-Dnp + H2O
?
show the reaction diagram
-
-
-
-
?
7-amido-4-carboxymethylcoumarin-YVADAPK(Dnp)-OH + H2O
dinitrophenol + 7-amino-4-carbamoylmethylcoumarin-YVADAPK
show the reaction diagram
-
-
-
-
?
Abz-FRK(Dnp)P-OH + H2O
Abz-FR K(Dnp)P
show the reaction diagram
-
-
-
-
?
Abz-LFK(Dnp)-OH + H2O
Abz-Leu + Phe-Lys(Dnp)-OH
show the reaction diagram
-
-
-
-
?
Abz-LFK(Dnp)-OH + H2O
Abz-Leu-Phe + NG-Dnp-Lys
show the reaction diagram
-
-
-
-
?
Abz-SDK(Dnp)P-OH + H2O
Abz-Ser-Asp + Lys(Dnp)-Pro
show the reaction diagram
-
-
-
-
?
Abz-YRK(2,4-dinitrophenyl)P + H2O
?
show the reaction diagram
-
-
-
-
?
acetyl-His-Pro-(NO2)Phe-His-Leu + H2O
acetyl-His-Pro-(NO2)Phe + His-Leu
show the reaction diagram
-
-
-
-
?
Ala-Ala-Ala-Ala + H2O
Ala-Ala + Ala-Ala
show the reaction diagram
Ala-Ala-Ala-Pro + H2O
Ala-Ala-Ala + Pro
show the reaction diagram
-
-
-
?
Ala-Phe-Ala + H2O
Ala-Phe + Ala
show the reaction diagram
-
-
-
-
?
amyloid beta-peptide(1-40) + H2O
amyloid beta-peptide(1-7) + amyloid beta-peptide(8-40)
show the reaction diagram
amyloid beta-protein 1-40 + H2O
amyloid beta-peptide(1-7) + amyloid beta-peptide(8-40)
show the reaction diagram
-
ACE cleaves amyloid beta-protein 1-40 between Asp7 and Ser8
-
-
?
amyloid beta-protein 1-42 + H2O
amyloid beta-peptide(1-40) + amyloid beta-peptide(41-42)
show the reaction diagram
-
ACE cleaves amyloid beta-protein 1-42 at multiple sites
-
-
?
amyloid beta-protein 1-42 + H2O
amyloid beta-protein 1-420 + ?
show the reaction diagram
angiotensin (1-9) + H2O
?
show the reaction diagram
-
-
-
-
?
Angiotensin I + H2O
?
show the reaction diagram
angiotensin I + H2O
angiotensin II + His-Leu
show the reaction diagram
angiotensin I + H2O
angiotensin II + L-His-L-Leu
show the reaction diagram
Angiotensin II + H2O
?
show the reaction diagram
-
converts Ang II to Ang(1-7)
-
-
?
Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 + H2O
?
show the reaction diagram
Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 + H2O
Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly + Leu-Met-NH2
show the reaction diagram
Arg-Pro-Pro-Gly-Phe-Ser-Pro-Tyr-Arg + H2O
?
show the reaction diagram
-
-
-
-
?
Arg-Pro-Pro-Gly-Phe-Thr-Pro-Phe-Arg + H2O
?
show the reaction diagram
-
-
-
-
?
Asn-Arg-Val-Tyr-Ile-His-Pro-(NO2)Phe-His-Leu + H2O
Asn-Arg-Val-Tyr-Ile-His-Pro-(NO2)Phe + His-Leu
show the reaction diagram
-
-
-
-
?
benzoyl-Gly-Ala-His-Leu + H2O
benzoyl-Gly-Ala + His-Leu
show the reaction diagram
-
-
-
-
?
benzoyl-Gly-Ala-Leu + H2O
benzoyl-Gly + Ala-Leu
show the reaction diagram
-
-
-
-
?
benzoyl-Gly-Ala-Pro + H2O
benzoyl-Gly + Ala-Pro
show the reaction diagram
benzoyl-Gly-Arg-His-Leu + H2O
benzoyl-Gly-Arg + His-Leu
show the reaction diagram
-
-
-
-
?
benzoyl-Gly-Arg-Leu + H2O
benzoyl-Gly + Arg-Leu
show the reaction diagram
-
-
-
-
?
benzoyl-Gly-Glu-Leu + H2O
benzoyl-Gly + Glu-Leu
show the reaction diagram
-
-
-
-
?
benzoyl-Gly-Gly-Gly + H2O
benzoyl-Gly + Gly-Gly
show the reaction diagram
benzoyl-Gly-His-Ala + H2O
benzoyl-Gly + His-Ala
show the reaction diagram
-
-
-
-
?
benzoyl-Gly-His-Leu + H2O
benzoyl-Gly + His-Leu
show the reaction diagram
benzoyl-Gly-His-Phe + H2O
benzoyl-Gly + His-Phe
show the reaction diagram
-
-
-
-
?
benzoyl-Gly-Ile-His-Leu + H2O
benzoyl-Gly-Ile + His-Leu
show the reaction diagram
-
-
-
-
?
benzoyl-Gly-Phe-Arg + H2O
benzoyl-Gly + Phe-Arg
show the reaction diagram
benzoyl-Gly-Phe-His-Leu + H2O
benzoyl-Gly-Phe + His-Leu
show the reaction diagram
-
-
-
-
?
benzoyl-Gly-Phe-Leu + H2O
benzoyl-Gly + Phe-Leu
show the reaction diagram
-
-
-
-
?
benzoyl-Gly-Pro-His-Leu + H2O
benzoyl-Gly-Pro + His-Leu
show the reaction diagram
-
-
-
-
?
benzoyl-Gly-Ser-His-Leu + H2O
benzoyl-Gly-Ser + His-Leu
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-(NO2)Phe-His-Leu + H2O
benzyloxycarbonyl-(NO2)Phe + His-Leu
show the reaction diagram
benzyloxycarbonyl-Gly-Gly-Gly + H2O
benzyloxycarbonyl-Gly + Gly-Gly
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Leu-Gly-Gly + H2O
benzyloxycarbonyl-Leu + Gly-Gly
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-His-Leu + H2O
?
show the reaction diagram
benzyloxycarbonyl-Phe-His-Leu + H2O
benzyloxycarbonyl-Phe + His-Leu
show the reaction diagram
benzyloxycarbonyl-Phe-Tyr-Leu
benzyloxycarbonyl-Phe + Tyr-Leu
show the reaction diagram
-
-
-
-
?
beta-neoendorphin + H2O
?
show the reaction diagram
-
-
-
-
?
Bradykinin + H2O
?
show the reaction diagram
bradykinin + H2O
Arg-Pro-Pro-Gly-Phe + Ser-Pro + Phe-Arg
show the reaction diagram
-
i.e. Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg
-
-
?
bradykinin + H2O
L-Phe-L-Arg + L-Ser-L-Pro + L-Arg-L-Pro-L-Pro-Gly-L-Phe
show the reaction diagram
-
-
-
-
?
bradykinin + H2O
Phe-Arg + Ser-Pro + Arg-Pro-Pro-Gly-Phe
show the reaction diagram
cholecystokinin-8 + H2O
?
show the reaction diagram
-
-
-
-
?
dansyltriglycine + H2O
?
show the reaction diagram
-
-
-
-
?
dynorphin + H2O
?
show the reaction diagram
-
-
-
-
?
furanacryloyl-L-Phe-Gly-Gly + H2O
furanacryloyl-L-Phe + Gly-Gly
show the reaction diagram
Gly-Ala-Ala + H2O
Gly + Ala-Ala
show the reaction diagram
-
-
-
?
Gly-Gly-Tyr-Arg + H2O
Gly-Gly + Tyr-Arg
show the reaction diagram
-
-
-
?
Gly-His-Gly + H2O
Gly + His-Gly
show the reaction diagram
-
-
-
?
Gly-Ile-His-Pro-(NO2)Phe-His-Leu + H2O
Gly-Ile-His-Pro-(NO2)Phe + His-Leu
show the reaction diagram
-
-
-
-
?
Gly-Pro-(NO2)Phe-His-Leu + H2O
Gly-Pro-(NO2)Phe + His-Leu
show the reaction diagram
-
-
-
-
?
gonadotropin-releasing hormone + H2O
?
show the reaction diagram
-
a bridging interaction between Arg500 of the N-domain and Arg8 of gonadotropin-releasing hormone that involves a buried chloride ion may account for its role in the specificity of the N-domain for endoproteolytic cleavage of the substrate at the NH2-terminus in vitro
-
-
?
hippuryl-Gly-Gly + H2O
hippuric acid + Gly-Gly
show the reaction diagram
hippuryl-Gly-His-Leu + H2O
hippuric acid + His-Leu
show the reaction diagram
-
-
-
?
hippuryl-His-Leu + H2O
hippuric acid + His-Leu
show the reaction diagram
hippuryl-histidyl-leucine + H2O
?
show the reaction diagram
-
-
-
-
?
hippuryl-L-His-L-Leu + H2O
hippuric acid + L-His-L-Leu
show the reaction diagram
hippuryl-Lys-Leu + H2O
hippuric acid + Lys-Leu
show the reaction diagram
-
-
-
-
?
hippuryl-Phe-Arg + H2O
hippuric acid + Phe-Arg
show the reaction diagram
His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2 + H2O
His-Lys-Thr-Asp-Ser-Phe-Val-Gly + Leu-Met-NH2
show the reaction diagram
-
i.e. substance K, degraded by striatal but not by lung enzyme
-
-
?
His-Pro-(NO2)Phe-His-Leu + H2O
His-Pro-(NO2)Phe + His-Leu
show the reaction diagram
-
-
-
-
?
Ile-Ser-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg + H2O
?
show the reaction diagram
-
-
-
-
?
LEQIYHL + H2O
?
show the reaction diagram
Leu5-enkephalin + H2O
Tyr-Gly-Gly + Phe-Leu
show the reaction diagram
Luteinizing hormone-releasing hormone + H2O
?
show the reaction diagram
-
degraded by striatal and by lung enzyme
-
-
?
LVVYPWTQRY + H2O
LVVYPWTQ + RY + LVVY + PW + LVVYPW + TQ
show the reaction diagram
-
-
dipeptide TQ is unidentified. Sequential removal of dipeptides in three consecutive steps
?
MCA-Ala-Ser-Asp-Lys-Dap(DNP)-OH + H2O
?
show the reaction diagram
angiotensin-converting enzyme
-
-
?
Mca-RPPGFSAFK(Dnp)-OH + H2O
?
show the reaction diagram
-
-
-
-
?
MCA-Tyr-Val-Ala-Asp-Ala-Pro-Lys(DNP)-OH + H2O
?
show the reaction diagram
angiotensin-converting enzyme 2
-
-
?
Met5-enkephalin + H2O
Tyr-Gly-Gly + Phe-Met
show the reaction diagram
Met5-enkephalin-Arg6-Gly7-Leu8 + H2O
Tyr-Gly-Gly-Phe-met-Arg + Gly-Leu
show the reaction diagram
-
-
-
-
?
MKRSRGPSPRR + H2O
?
show the reaction diagram
-
-
-
-
?
N-(1-(S)-carboxy-3-phenylpropyl)-L-Ala-L-Pro + H2O
?
show the reaction diagram
-
i.e. MK-422
-
-
?
N-(1-(S)-carboxy-3-phenylpropyl)-L-Lys-L-Pro + H2O
?
show the reaction diagram
-
i.e. MK-522
-
-
?
N-(3-(2-furyl)acryloyl)-L-Phe-Gly-Gly + H2O
2-furylacrylic acid + L-Phe-Gly-Gly
show the reaction diagram
-
-
-
?
N-(3-(2-furyl)acryloyl)-L-Phe-Gly-Gly + H2O
N-(3-(2-furyl)acrylic acid) + Phe-Gly-Gly
show the reaction diagram
-
-
-
?
N-(3-(2-furyl)acryloyl)-L-Phe-Phe-Arg + H2O
2-furylacrylic acid + L-Phe-Phe-Arg
show the reaction diagram
-
-
-
?
N-(3-(2-furyl)acryloyl)-Phe-Ala-Ala + H2O
2-furylacrylic acid + Phe-Ala-Ala
show the reaction diagram
-
-
-
?
N-(3-(2-furyl)acryloyl)-Phe-Ala-Gly + H2O
2-furylacrylic acid + Phe-Ala-Gly
show the reaction diagram
-
-
-
?
N-(3-(2-furyl)acryloyl)-Phe-Ala-Lys + H2O
2-furylacrylic acid + Phe-Ala-Lys
show the reaction diagram
-
-
-
?
N-(3-(2-furyl)acryloyl)-Phe-Ala-Pro + H2O
2-furylacrylic acid + Phe-Ala-Pro
show the reaction diagram
-
-
-
?
N-(3-(2-furyl)acryloyl)-Phe-Gly-Gly + H2O
2-furylacrylic acid + Phe-Gly-Gly
show the reaction diagram
-
-
-
?
N-(3-(2-furyl)acryloyl)-Phe-Phe-Arg + H2O
2-furylacrylic acid + Phe-Phe-Arg
show the reaction diagram
-
-
-
?
N-acetyl-Ala-Ala-Ala + H2O
N-acetyl-Ala + Ala-Ala
show the reaction diagram
-
-
-
?
N-hippuryl-His-Leu + H2O
hippuric acid + His + Leu
show the reaction diagram
-
-
-
?
N-hippuryl-His-Leu + H2O
hippuric acid + His-Leu
show the reaction diagram
N-hippuryl-His-Leu + H2O
N-hippuric acid + His-Leu
show the reaction diagram
-
-
-
-
?
N-[3-(2-furyl)acryloyl]-L-Phe-Gly-Gly + H2O
2-furylacrylic acid + L-Phe-Gly-Gly
show the reaction diagram
-
-
-
-
?
N-[3-(2-furyl)acryloyl]-L-phenylalanyl-glycyl-glycine + H2O
?
show the reaction diagram
-
-
-
-
?
N-[3-(2-furyl)acryloyl]-L-phenylalanyl-glycyl-glycine + H2O
N-[3-(2-furyl)acryloyl]-L-phenylalanine + glycyl-glycine
show the reaction diagram
N-[3-(2-furyl)acryloyl]-Phe-Gly-Gly + H2O
N-[3-(2-furyl)acryloyl]-Phe + Gly-Gly
show the reaction diagram
-
-
-
-
?
neurotensin + H2O
pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr + Ile-Leu
show the reaction diagram
NKLKPSQ + H2O
?
show the reaction diagram
NKLKPSQWI + H2O
?
show the reaction diagram
NKLKPSQWISL + H2O
?
show the reaction diagram
NKLKPSQWISLSD + H2O
?
show the reaction diagram
o-aminobenzoyl-FDK-(dinitrophenyl)-P-OH + H2O
o-aminobenzoyl-FD + K-(dinitrophenyl)-P-OH
show the reaction diagram
-
-
-
?
o-aminobenzoyl-FRK-(dinitrophenyl)-P-OH + H2O
o-aminobenzoyl-FR + K-(dinitrophenyl)-P-OH
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFAQ-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFA + Gln-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFEQ-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFE + Gln-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFFQ-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFF + Gln-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFLQ-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFL + Gln-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFQQ-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFQ + Gln-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFRA-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFR + Ala-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFRF-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFR + Phe-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFRI-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFR + Ile-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFRN-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFR + Asn-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFRQ-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFR + Gln-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFRR-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFR + Arg-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFRS-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFR + Ser-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFSQ-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFS + Gln-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-Phe-Arg-Lys(2,4-dinitrophenyl)-Pro-hydroxide + H2O
?
show the reaction diagram
-
-
-
-
?
o-aminobenzoyl-SDK-(dinitrophenyl)-P-OH + H2O
o-aminobenzoyl-SD + K-(dinitrophenyl)-P-OH
show the reaction diagram
-
-
-
?
o-aminobenzoyl-SRK-(dinitrophenyl)-P-OH + H2O
o-aminobenzoyl-SR + K-(dinitrophenyl)-P-OH
show the reaction diagram
-
-
-
?
o-aminobenzoyl-TDK-(dinitrophenyl)-P-OH + H2O
o-aminobenzoyl-TD + K-(dinitrophenyl)-P-OH
show the reaction diagram
-
-
-
?
o-aminobenzoyl-TRK-(dinitrophenyl)-P-OH + H2O
o-aminobenzoyl-TR + K-(dinitrophenyl)-P-OH
show the reaction diagram
-
-
-
?
o-aminobenzoyl-YDK-(dinitrophenyl)-P-OH + H2O
o-aminobenzoyl-YD + K-(dinitrophenyl)-P-OH
show the reaction diagram
-
-
-
?
o-aminobenzoyl-YRK-(dinitrophenyl)-P-OH + H2O
o-aminobenzoyl-YR + K-(dinitrophenyl)-P-OH
show the reaction diagram
-
-
-
?
p-hydroxyhippuryl-His-Leu + H2O
?
show the reaction diagram
-
-
-
?
p-nitrobenzyloxycarbonyl-Gly + H2O
?
show the reaction diagram
-
-
-
-
?
p-nitrobenzyloxycarbonyl-Gly-Gly-Gly + H2O
?
show the reaction diagram
-
-
-
-
?
Phe-Gly-Gly-Phe + H2O
Phe-Gly + Gly-Phe
show the reaction diagram
-
-
-
?
physalaemin + H2O
pGlu-Ala-Asp-Pro-Asn-Lys-Phe-Tyr-Gly + Leu-Met-NH2
show the reaction diagram
-
degraded by striatal and by lung enzyme
-
-
?
Pro-(NO2)Phe-His-Leu + H2O
Pro-(NO2)Phe + His-Leu
show the reaction diagram
-
-
-
-
?
SLKPSNWLTPSE + H2O
?
show the reaction diagram
tert-butoxycarbonyl-Phe-Ala-Pro + H2O
tert-butoxycarbonyl-Phe + Ala-Pro
show the reaction diagram
-
-
-
-
?
tert-butoxycarbonyl-Phe-Phe-Gly + H2O
tert-butoxycarbonyl-Phe + Phe-Gly
show the reaction diagram
-
-
-
-
?
Tyr-Gly-Gly + H2O
Tyr + Gly-Gly
show the reaction diagram
-
-
-
-
?
Tyr-Gly-Gly-Phe-Leu + H2O
Tyr-Gly-Gly + Phe-Leu
show the reaction diagram
-
-
-
?
Tyr-Gly-Gly-Phe-Met + H2O
Tyr-Gly-Gly + Phe-Met
show the reaction diagram
-
-
-
?
Tyr-Gly-Gly-Phe-Met-Arg-Gly-Leu + H2O
Tyr-Gly-Gly-Phe-Met-Arg + Gly-Leu
show the reaction diagram
-
-
-
-
?
Tyr-Ile-His-Pro-(NO2)Phe-His-Leu + H2O
Tyr-Ile-His-Pro-(NO2)Phe + His-Leu
show the reaction diagram
-
-
-
-
?
Z-Phe-His-Leu + H2O
Z-Phe + His-Leu
show the reaction diagram
-
-
-
-
?
Z-phenylalanyl-histidyl-leucine + H2O
Z-phenylalanine + histidyl-leucine
show the reaction diagram
-
-
-
-
?
[Arg10]angiotensin I + H2O
?
show the reaction diagram
-
-
-
-
?
[D-Ala2,Leu5]enkephalin + H2O
Tyr-D-Ala-Gly + Phe-Leu
show the reaction diagram
-
-
-
-
?
[Leu5]enkephalin + H2O
?
show the reaction diagram
-
-
-
-
?
[Leu5]enkephalinamide + H2O
?
show the reaction diagram
-
-
-
-
?
[Met5]enkephalin + H2O
?
show the reaction diagram
-
-
-
-
?
[Met5]enkephalinamide + H2O
?
show the reaction diagram
-
-
-
-
?
[Phe9,Arg10]angiotensin I + H2O
?
show the reaction diagram
-
-
-
-
?
[Phe9]angiotensin I + H2O
?
show the reaction diagram
-
-
-
-
?
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
amyloid beta-peptide(1-40) + H2O
amyloid beta-peptide(1-7) + amyloid beta-peptide(8-40)
show the reaction diagram
-
cleavage at the Asp7-Ser9 bond. Compared with amyloid beta-peptide(1-40), aggregation and cytotoxic effects of the degradation products amyloid beta-peptide(1-7) and amyloid beta-peptide(8-40) are reduced ot virtually absent. The enzyme inhibits aggregation, deposition, and cytotoxicity of amyloid beta-peptide in vitro may affect susceptibility to Alzheimer‘s disease
-
?
amyloid beta-protein 1-40 + H2O
amyloid beta-peptide(1-7) + amyloid beta-peptide(8-40)
show the reaction diagram
-
ACE cleaves amyloid beta-protein 1-40 between Asp7 and Ser8
-
-
?
amyloid beta-protein 1-42 + H2O
amyloid beta-peptide(1-40) + amyloid beta-peptide(41-42)
show the reaction diagram
-
ACE cleaves amyloid beta-protein 1-42 at multiple sites
-
-
?
amyloid beta-protein 1-42 + H2O
amyloid beta-protein 1-420 + ?
show the reaction diagram
angiotensin I + H2O
angiotensin II + His-Leu
show the reaction diagram
angiotensin I + H2O
angiotensin II + L-His-L-Leu
show the reaction diagram
Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 + H2O
?
show the reaction diagram
-
i.e. substance P, lung and brain ACE cleave substance P via two pathways. In one pathway ACE first releases Gly-Leu-Met-NH2 and then dipeptides sequentially from the carboxyl terminus. The other first produces Leu-Met-NH2 and then releases dipeptides to leave substance P(1-5)
-
-
-
Bradykinin + H2O
?
show the reaction diagram
bradykinin + H2O
L-Phe-L-Arg + L-Ser-L-Pro + L-Arg-L-Pro-L-Pro-Gly-L-Phe
show the reaction diagram
-
-
-
-
?
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
CaCl2
-
activates in absence of Cl-, maximal activity at 0.3 mM
Cl-
-
the activity of the C-domain of sACE depends highly on chloride ion concentration and is inactive in its absence, whereas the N-domain can be completely activated at relatively low concentrations of this anion and is still active in the absence of chloride
CoCl2
-
0.1-1.0 mM, 2fold activation
KBr
-
activation is lower than with NaCl
KI
-
activation is lower than with NaCl
Na2SO4
-
activates in absence of Cl-
NaF
-
activation is lower than with NaCl
additional information
-
enzyme is not affected by addition of 0.1-1.0 mM CaCl2, Mn2Cl2, MgCl2 or 0.1 mM ZnCl2
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(+)-catechin
-
IC50: about 1.6 mM
(-)-epicatechin
-
IC50: about 1.7 mM
(2E)-3-(3-amino-4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(3-fluoro-4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(3-hydroxy-4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(3-hydroxy-4-nitrophenyl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(3-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-hydroxy-3-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-methoxy-3-nitrophenyl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-phenyl-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
-
(2R)-2-((3-[hydroxyl (2-phenyl-(1R)-1-([(benzyloxy) carbonyl]-amino)ethyl)phosphinyl]-2-[(3-phenylisoxazol-5-yl)methyl]-1-oxopropyl)amino)-3-(4-hydroxy-phenyl) propanoic acid
(2S)-1-((3S)-3-amino-3-carboxypropyl)azetidine-2-carboxylic acid
-
IC50: 0.0033 mM
(2S)-2-((3-[hydroxyl (2-phenyl-(1R)-1-([(benzyloxy) carbonyl]-amino)ethyl)phosphinyl]-2-[(3-phenylisoxazol-5-yl)methyl]-1-oxopropyl)amino)-3-(4-hydroxy-phenyl) propanoic acid
(2S)-2-((3-[hydroxyl(2-phenyl-(1R)-1([(benzyloxy)carbonyl]amino)ethyl)phosphinyl]-(2R)-2-[(3-phenylisoxazol-5-yl)methyl]-1-oxopropyl)amino)-3-phenyl propanoic acid
-
-
(2S)-2-((3-[hydroxyl(2-phenyl-(1R)-1-([(benzyloxy)carbonyl]-amino)ethyl)phosphinyl]-(2R)-2-[(3-phenylisoxazol-5-yl)methyl]-1-oxopropyl)amino) 1H-Indole-3-propanoic acid
-
-
(2S)-2-((3-[hydroxyl(2-phenyl-(1R)-1-([(benzyloxy)carbonyl]-amino)ethyl)phosphinyl]-(2R)-2-[(3-phenylisoxazol-5-yl)methyl]-1-oxopropyl)amino)-3-(4-hydroxy-phenyl) propanoic acid
-
-
(2S)-2-((3-[hydroxyl(2-phenyl-(1R)-1-([(benzyloxy)carbonyl]-amino)ethyl)phosphinyl]-(2S)-2-[(3-phenylisoxazol-5-yl)methyl]-1-oxopropyl)amino) 1H-indole-3-propanoic acid
-
-
(2S)-2-((3-[hydroxyl(2-phenyl-(1R)-1-([(benzyloxy)carbonyl]-amino)ethyl)phosphinyl]-(2S)-2-[(3-phenylisoxazol-5-yl)methyl]-1-oxopropyl)amino)-3-(4-hydroxy-phenyl) propanoic acid
-
-
(2S)-2-([3-(1,1'-biphenyl)-2-([hydroxyl(2-phenyl-(1R)-1-([(benzyloxy)carbonyl]amino)ethyl)phosphinyl]methyl)-1-oxopropyl]-amino) 1H-indole-3-propanoic acid
-
-
(2S)-2-([3-(3'-[1,1'-biphenyl]-4''-yl-4',5'-dihydro-5'-isoxazolyl)-2-([hydroxyl(2-phenyl-(1R)-1-([(benzyloxy)carbonyl]amino)ethyl)-phosphinyl]methyl)-1-oxopropyl]amino) 1H-indole-3-propanoic acid
-
-
(2S)-2-[[(2S)-2-mercapto-3-methylpentanoyl]amino]-3-(1-naphthyl)propanoic acid
;
(2S)-2-[[(2S)-2-mercapto-3-methylpentanoyl]amino]-3-(2-naphthyl)propanoic acid
-
;
(2S)-2-[[(2S)-2-mercapto-3-methylpentanoyl]amino]-3-phenylpropanoic acid
;
(2S)-2-[[(2S)-2-mercapto-3-methylpentanoyl]amino]propanoic acid
;
(2S)-3-(4-hydroxyphenyl)-2-[[(2S)-2-mercapto-3-methylpentanoyl]amino]propanoic acid
;
(2S)-3-biphenyl-2-yl-2-[[(2S)-3-methyl-2-sulfanylpentanoyl]amino]propanoic acid
-
;
(2S)-3-biphenyl-3-yl-2-[[(2S)-3-methyl-2-sulfanylpentanoyl]amino]propanoic acid
-
;
(2S)-3-biphenyl-4-yl-2-[(2-mercapto-2-methylpropanoyl)amino]propanoic acid
;
(2S)-3-biphenyl-4-yl-2-[(mercaptoacetyl)amino]propanoic acid
;
(2S)-3-biphenyl-4-yl-2-[[(2S)-2-mercaptobutanoyl]amino]propanoic acid
;
(2S)-3-biphenyl-4-yl-2-[[(2S)-2-mercaptopropanoyl]amino]propanoic acid
;
(2S)-3-biphenyl-4-yl-2-[[(2S)-3-methyl-2-sulfanylpentanoyl]amino]propanoic acid
-
;
(5S)-5-[(N-benzoyl)-amino]-4-oxo-6-phenyl-hexanoyl-L-phenylalanine
-
phosphinic peptide inhibitor kAF
(5S)-5-[(N-benzoyl)amino]-4-oxo-6-phenylhexanoyl-L-phenylalanine
-
the inhibitor has a 30fold higher affinity for the C domain than for the N domain of ACE
(5S)-5-[(N-benzoyl)amino]-4-oxo-6-phenylhexanoyl-L-tryptophan
(pE)KWAP
-
-
(pE)WPRPQIPP
-
-
1,10-phenanthroline
1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide metho-p-toluene sulfonate
-
20 mM, 99.6% inhibition
1-Fluoro-2,4-dinitrobenzene
1-methyl-5-phenyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-pyrazole
-
-
1-[(5S)-4-oxo-6-phenyl-5-[(phenylcarbonyl)amino]hexanoyl]-L-proline
-
1-[(5S)-5-[(tert-butoxycarbonyl)amino]-4-oxo-6-phenylhexanoyl]-L-proline
-
15 B1
-
-
15 B2
-
-
15B2
-
an inhibitor isolated from the culture broth of Actinomadura sp. No. 937ZE-1
2''-hydroxynicotianamide
-
angiotensin-I converting enzyme inhibitor from buckwheat (Fagopyrum esculentum Moench) flour, IC50: 0.00008 mM
2,3-butendione
-
10 mM, 97.4% inhibition
2,3-dimercapto-1-propanol
-
-
2-(benzyloxy)-N-[(2S)-3-methyl-2-sulfanylpentanoyl]-L-phenylalanine
-
;
2-hydroxyemodin 1-methylether
-
47.52% inhibition at 1.63 ng/ml
2-mercaptoethanol
2-methoxy-4-[1-methyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenol
-
-
2-methoxy-5-[1-methyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]aniline
-
-
2-methoxy-5-[1-methyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenol
-
-
2-[([2-[(1-[[(benzyloxy)carbonyl]amino]-2-phenylethyl)(hydroxy)phosphoryl]cyclopentyl]carbonyl)amino]-3-(2,3-dihydro-1H-indol-3-yl)propanoate
-
-
3,6-Dihydroxy-1-phenazinecarboxylic acid
-
i.e. phenacein, competitive, reversed by Zn2+, isolated from a member of Streptomyces tanashiensis-zaomyceticus
3-(benzyloxy)-N-[(2S)-3-methyl-2-sulfanylpentanoyl]-L-phenylalanine
-
;
3-mercapto-2-D-methylpropanoyl-L-Pro
-
i.e. SQ-14,225
3-p-acetyl-aminophenylpropionate
-
-
3-p-aminophenylpropionate
-
-
3-Phenylpropionate
-
-
4-coumaric acid
4-hydroxybenzoic acid
4-phenylbutyrate
-
-
5'-ATP
-
-
5-(3-fluoro-4-methoxyphenyl)-1-methyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-pyrazole
-
-
5-(3-methoxyphenyl)-1-methyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-pyrazole
-
-
5-(4-methoxy-3-nitrophenyl)-1-methyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-pyrazole
-
-
5-(4-methoxyphenyl)-1-methyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-pyrazole
-
-
5-[1-methyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]-2-nitrophenol
-
-
8-hydroxyquinoline
-
-
9-[1-carboxy-3-(4-hydroxyphenyl)propylamino]octahydro-10-oxo-6H-pyridazo[1,2-a][1,2]diazepine-1-carboxylic acid
-
-
-
A 58365A
-
-
A 58365B
-
-
Ac-FKCRRWQWRMKKLGA-NH2
-
0.02 mM, 38% loss of activity with hippuryl-His-Leu, 41% loss of activity with angiotensin I
Ac-RKKPFW-NH2
-
0.02 mM, 24% loss of activity with hippuryl-His-Leu
Ac-RKWHFW-NH2
-
0.02 mM, 42% loss of activity with hippuryl-His-Leu, 55% loss of activity with angiotensin I; 0.02 mM, 48% loss of activity with hippuryl-His-Leu
Ac-RKWLFW-NH2
-
0.02 mM, 26% loss of activity with hippuryl-His-Leu, 71% loss of activity with angiotensin I; 0.02 mM, 32% loss of activity with hippuryl-His-Leu
Ac-RKWRFW-NH2
-
0.02 mM, 3% loss of activity with hippuryl-His-Leu
Ac-RRWQWR-NH2
-
0.02 mM, 29% loss of activity with hippuryl-His-Leu, 34% loss of activity with angiotensin I
acetate
-
-
Acetyl-Ala-Ala-Ala
-
hydrolysis of hippuryl-His-Leu
Acetyl-Ala-Ala-Ala-Ala
-
hydrolysis of hippuryl-His-Leu
acidic protease
-
about 80% ACE inhibitory
-
acteoside
-
a phenylpropanoid glycoside isolated from ethanolic extracts of seeds of Plantago asiatica, collected from Jiang Xi Province in China. The compound shows ACE inhibitory activity in vitro, structure analysis by NMR, UV, IR and MS
Ala-Ala
Ala-Ala-Ala
-
hydrolysis of hippuryl-His-Leu
Ala-Ala-Ala-Ala
-
hydrolysis of hippuryl-His-Leu
Ala-Gly-Ser
-
-
Ala-Gly-Ser-Pro
-
-
Ala-Gly-Ser-Ser
-
-
Ala-His-Ser-Tyr
-
a noncompetitive inhibitor, the peptide is resistant to further degenration by pepsin, trypsin, and chymotrypsin
Ala-Leu-Pro-His-Ala
Ala-Phe
Ala-Pro-Gly-Ala-Gly-Val-Tyr
-
-
Ala-Trp
Ala-Trp-Pro-Phe
-
-
Ala-Tyr
Ala-Val-Val
-
-
alaternin
-
24.26% inhibition at 1.63 ng/ml
alcacepril
-
synthetic ACE inhibitor and antihypertensive drug
alcalase
-
about 20% ACE inhibitory
-
aliphatic monocarboxylates
-
degree of inhibition increases in proportion to their chain length up to C14
-
aminoethyl-chitin
-
with 10%, 50%, and 90% deacetylation
ancovenin
-
-
angiotensin converting enzyme inhibitor
-
ACE-I, inhibition is impacting both the renin-angiotensin cascade and the degradation metabolism of bradykinin, inhibition mechanism, overview. ACE-I is used as therapeutic agent in congestive heart failure, diabetic nephropathy, hypertension, and coronary artery disease. ACE-I medications can induce chronic cough, hypotension, hyperkalemia, bone marrow depression, angioedema, and rarely, hepatic failure. Angioedema involves a subcutaneous swelling reaction that evolves over several hours and is not associated with itching or pain, pathomechanism, detailed overview
-
angiotensin I
angiotensin I converting enzyme inhibitory peptides
-
from wheat milling byproducts by proteolysis through aspartic proteases, optimally produced at pH 3.2. Milled whole grain, bran, shorts, and red dog acquire ACE inhibitory activity though water soaking treatment, preparation of shorts exhibits the strongest inhibitory activity with an IC50 value of 0.08 mg/ml, overview
-
angiotensin I-converting enzyme inhibitory peptides
-
i.e. ACE-Is, from enzymatic hydrolysates of cuttlefish, Sepia officinalis, muscle proteins, generated by the crude enzyme from Bacillus mojavensis A21, show 87.11% inhibition at 2 mg/ml, mass spectrometric analysis, overview
-
angiotensin II
Angiotensin III
-
-
angiotensin IV
-
IC50: 0.07 mM
angiotensin-converting enzyme inhibitor
-
ACEi, induces angioedema, a non-allergic bradykinin-induced drug side-effect and clinical life-threatening problem, overview. ACE insertion/deletion and bradykinin B2 receptor polymorphisms are not involved in the development of ACEi-induced angio-oedema
-
angiotensin-I converting enzyme inhibitory peptides
-
activity of hydrolysates, using diverse proteases, from Avena sativa proteins by in silico and in vitro analyses, peptide sequencing, overview
-
antipain
-
0.1 mg/ml, 26% inhibition
apigenin
Arg-Ala
-
hydrolysis of hippuryl-His-Leu
Arg-Met-Leu
-
IC50: 1.019 mM, competitive inhibition
Arg-Phe
-
IC50: 4.365 mM
Arg-Pro-Pro
Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg
-
hydrolysis of hippuryl-His-Leu
Asn-Phe
-
-
Asn-Trp-Gly-Pro-Leu-Val
-
-
Asn-Tyr
-
-
Asp-Ala
-
hydrolysis of hippuryl-His-Leu
Asp-Asp-Thr-Gly-His-Asp-Phe-Glu-Asp-Thr-Gly-Glu-Ala-Met
-
an inhibitory peptide from the marine rotifer, Brachionus rotundiformis
Asp-Gly
-
-
Asp-Ile-Gly-Tyr-Tyr
-
-
Asp-Leu-Pro
-
-
Asp-Phe-Gly
-
-
Asp-Tyr-Gly-Leu-Tyr-Pro
-
-
Asp-Tyr-Val-Gly-Asn
-
-
aspergillomarasmine A
-
-
aspergillomarasmine B
-
-
benazepril
benazeprilat
benzapril
-
-
benzenesulfonate
-
-
Benzoate
-
-
Benzoic acid
benzoyl-NHCOCH2CH(COOH)-Ala-Pro-OH
-
-
benzoyl-NHCOCH2CH(COOH)-Trp-Pro-OH
-
-
benzyloxycarbonyl-PhePSI[PO2-CH]Ala-Ala
-
-
benzyloxycarbonyl-PhePSI[PO2-CH]Ala-Trp
-
-
Bothrops bradykinin potentiating peptides
-
-
-
bradykinin
bradykinin potentating factor nonapeptide
-
-
-
bradykinin potentiating peptide
i.e. BPP1 or pGlu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro
-
bradykinin potentiating peptide b
-
interaction with sACE in a Zn-dependent manner
-
bradykinin potentiator B
-
-
bradykinin potentiator C
Bradykinin-potentiating factor SQ 20881
-
-
bradykinin-potentiating peptide 9a
-
-
bradykinin-potentiator B
-
-
bradykinin-potentiator C
-
-
caffeic acid
caffeoyl acetate
-
-
captopril
catechin
-
IC50: 1.593 mM, competitive
catechol
CGS-35066
-
-
chitooligosaccharide derivatives
chitosan trimer
-
effective in lowering blood pressure
chloramine-T
-
50 mM, 97.1% inhibition
chlorogenic acid
cilazapril
-
-
citrate
-
-
Cl-
-
kcat increases with increasing KCl concentrations, reaches a maximum at about 300 mM KCl, and the begins to decrease. At relatively low concentrations chloride anions activate the C-domain of the enzyme, but at high concentrations chloride inhibits the enzyme activity. Presence of at least two chloride-binding sites in the C-domain of bovine enzyme: binding of chloride to one of the sites causes activation of the enzyme, whereas chloride binding to the second site results in inhibition of the enzymatic activity
concanavalin A
-
-
-
cyanide
-
-
cyanidin-3-O-beta-D-glucoside
-
isolated from flower buds of Rosa damascena. Metal ions might be involved in the inhibition
cyanidin-3-O-sambubioside
-
an anthocyanin isolated from Hibiscus sabdariffa calyces, competitive ACE inhibition reducing blood pressure in humans, IC50 is 0.0684 mg/ml
Cys
-
-
D-3-thio-2-methylpropanoyl-Pro
-
-
D-Cys-L-Pro
-
competitive to hippuryl-His-Leu
D-mannitol
delaprilat
-
weak
delphinidin-3-O-sambubioside
-
an anthocyanin isolated from Hibiscus sabdariffa calyces, competitive ACE inhibition reducing blood pressure in humans, IC50 is 0.0845 mg/ml
dexamethasone
-
markedly inhibits the plasma extravasion in the tracheal mucosa produced by substance P. The simultanous inhibition of neutral endopeptidase and angiotensin converting enzyme completely reverses the effect of dexamethasone on substance P-induced extravasion
dieckol
diethyl dicarbonate
-
10 mM, 92.8% inhibition
dimethyl phosphate
-
-
diphosphate
-
-
dithiothreitol
-
-
DPVAPLQRSGPE
-
-
DPVAPLQRSGPEI
-
-
DPVAPLQRSGPEIP
-
-
DQVFPMNPPK
-
-
EDENNPFYLR
-
-
ELEIVMASPP
-
-
ellagic acid
emodin
-
45.79% inhibition at 1.63 ng/ml
enalapril
enalaprilat
enalaprilate
enapril
enaprilat
epicatechin
epicatechin dimer
-
IC50: 0.267 mM, competitive
epicatechin hexamer
-
IC50: 0.01 mM, competitive
epicatechin pentamer
-
IC50: 0.025 mM, competitive
epicatechin tetramer
-
IC50: 0.012 mM, competitive
epicatechin trimer
-
IC50: 0.126 mM, competitive
epigallocatechin
-
IC50: about 0.3 mM
ESIINF
-
the inhibitor produces an acute blood-pressure-lowering effect in spontaneously hypertensive rats upon a single oral administration
ethyl caffeate
-
0.01 mg/ml, 32.4% inhibition
EtOAc extract of Rabdosia coetsa
-
angiotensin-converting enzyme inhibitory activity
-
FDKPVSPL
-
-
ferulic acid
flavanol
-
flavanols either isolated or present in foods can inhibit enzyme activity
flavourzyme
-
about 20% ACE inhibitory
-
foroxymithine
-
-
fosinopril
fosinoprilat
-
-
gallic acid
gastrin I
-
-
genistein
-
0.003-0.3 mM genistein decreases the angiotensin-converting enzyme activity in blood plasma in a concentration-dependent manner; the isoflavone inhibits ACE in plasma and alters the vascular responses to angiotensin I and bradykinin, overview
Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro
-
-
gluco-aurantioobtusin
-
competitive inhibitor, 137.62% inhibition at 1.63 ng/ml
Gly-Asp-Ala-Pro
-
-
Gly-Gln
-
IC50: 5.63 mM, competitive inhibition
Gly-Glu-Pro
-
-
Gly-Gly-Val-Ile-Pro-Asn
-
-
Gly-His-Gly
-
-
Gly-L-Ala-Hyp-Gly-L-Leu-Hyp-Gly-L-Pro
Gly-L-Ala-Hyp-Gly-L-Pro-L-Ala-Gly-L-Pro-Gly-Gly-L-Ile-Hyp-Gly-L-Glu-L-Arg-Gly
Gly-L-Ile-Hyp-Gly-L-Glu-L-Arg-Gly-L-Pro-L-Val-Gly-L-Pro-L-Ser-Gly
Gly-L-Leu-Hyp-Gly-L-Ser-L-Arg-Gly-L-Glu-L-Arg-Gly-L-Leu-Hyp-Gly
Gly-L-Thr-Gly
-
-
Gly-Leu-Pro
-
IC50: 1.62 mM
Gly-Phe
-
IC50: 10.471 mM
Gly-Phe-Hyp-Gly-Thr-Hyp-Gly-Leu-Hyp-Gly-Phe
Gly-Pro
-
IC50: 252.63 mM
Gly-Pro-Ala
-
inhibits hydrolysis of Gly-Ala-Ala
Gly-Pro-Leu
-
IC50: 2.65 mM
Gly-Pro-Pro
-
-
Gly-Trp
Gly-Tyr
Gly-Val-His-His-Ala
-
-
glycinin hydrolysate
-
-
-
GQGGP
-
extraction and characterization of an ACE inhibitor from the fruiting body of Pholiota adiposa ASI 24012, which can be used as an antihypertensive drug
guanethidine
-
weak
H2PO2-
-
-
H2S
-
Zn2+ but not Cd2+, Ca2+ or Mg2+ could counteract the inhibitory effect
HERDPTHIKWGD
HgCl2
-
-
His-His-Leu
-
-
His-Leu
Hyp-Gly-Leu-Hyp-Gly-Phe
-
0.01 mM
Hyp-Gly-Phe
-
IC50: 0.433 mM
Hyp-Gly-Thr-Hyp-Gly-Leu-Hyp-Gly-Phe
-
0.019 mM
hyperosid
-
IC50: 0.2 mM
Ile-Ala
-
-
Ile-Ala-Tyr-Lys-Pro-Ala-Gly
-
-
Ile-Ala-Val
-
-
Ile-Asn-Ser-Gln
-
-
Ile-Gln-Pro
-
-
Ile-Glu-Pro
Ile-Glu-Trp
Ile-Glu-Tyr
Ile-Lys-Pro
Ile-Lys-Pro-Leu-Asn-Tyr
-
-
Ile-Lys-Trp
Ile-Lys-Tyr
Ile-Phe-Leu
-
-
Ile-Pro-Pro
Ile-Pro-Pro-Gly-Val-Pro-Tyr
-
-
Ile-Pro-Pro-Gly-Val-Pro-Tyr-Trp-Thr
-
-
Ile-Thr-Phe
-
-
Ile-Trp
Ile-Trp-His-His-Thr
Ile-Tyr
Ile-Tyr-Leu-Leu
-
-
Ile-Val-Gly-Arg-Pro-Arg-His-Gln-Gly
-
-
Ile-Val-Tyr
-
-
imidapril
-
-
imidaprilat
-
-
inhibitory peptides from rice dreg hydrolysate
-
significant antihypertensive action and no other side effects by oral administration in spontaneous hypertension rats
-
iodoMK-351A
-
-
-
IPPGVPYWT
-
-
isoacteoside
-
a phenylpropanoid glycoside isolated from ethanolic extracts of seeds of Plantago asiatica, collected from Jiang Xi Province in China. The compound shows ACE inhibitory activity in vitro, structure analysis by NMR, UV, IR and MS
isoquercitrin
-
IC50: 0.3 mM
isorhamnetin-3-beta-glucopyranoside
-
IC50: 0.4089 mM
ITTNPY
-
-
K-13
-
-
K-26
-
-
-
kaempferol
kaempferol-3-alpha-arabinopyranoside
-
IC50: 0.3928 mM
kaempferol-3-O-alpha-L-arabinopyranoside
-
-
kaempferol-3-O-beta-D-galactopyranoside
-
-
KAPVA
-
a peptide derived from muscle titin
KRQKYDI
-
competitive inhibitor, the strongest inhibitor among reported troponin-originated peptides. The inhibhitor is slowly hydrolyzed by treatment with angiotensin I-converting enzyme. When KRQKYDI is administered orally to spontaneously hypertensive rats at a dose of 10 mg/kg, a temporary antihypertensive activity is observed at 3 and 6 h after administration
L-681,176
L-Ala-L-Trp
L-Asp-L-Pro
-
-
L-Cys-L-Pro
-
-
L-Glu-L-Arg-L-Tyr-L-Pro-L-Ile
-
-
L-Ile-L-Pro-L-Phe
-
-
L-Leu-L-Pro-L-Phe
-
-
L-Met-L-Pro-L-Phe
-
-
L-Ser-L-Thr
-
-
L-Thr-L-Thr-L-Ile
-
-
L-Tyr-L-Thr-L-Ala-Gly-L-Val
-
-
L-Val-L-Asp-L-Phe
-
-
L-Val-L-Phe
L-Val-L-Tyr
laurate
-
-
leptin
-
-
-
Leu-Ala
-
hydrolysis of hippuryl-His-Leu
Leu-Ala-Ile-pro-Val-Asn-Lys-Pro
-
-
Leu-Arg-Ile-Pro-Val-Ala
-
-
Leu-Arg-Pro
-
-
Leu-Gln-Pro
Leu-Gly-Ile
-
-
Leu-Gly-Pro
-
IC50: 0.72 mM
Leu-Ile-Tyr
-
i.e. acein-2, isolated from tryptic hydrolysate of human plasma, non-competitive inhibitor, IC50: 0.00082 mM.
Leu-Lys-Pro
-
-
Leu-Lys-Pro-Asn-Met
-
-
Leu-Lys-Tyr
-
competitive
Leu-Phe
Leu-Pro-Gly
-
IC50: 5.73 mM
Leu-Trp
-
IC50: 0.0174 mM, non-competitive
Leu-Tyr
-
-
Leu-Tyr-Pro
-
-
Leu-Val-Tyr
-
competitive
Leupeptin
-
0.1 mg/ml, 18% inhibition
LFDKPVSPL
-
-
LGFPTTKTYFPHF
-
-
Lisinopril
lisW-S
LKPNM
-
-
LRPARPTSPP
-
-
LRPARPTSPPA
-
-
luteolin-7-O-beta-D-glucopyranoside
-
-
LVVYPWTQRF
-
-
Lys-Ala
-
hydrolysis of hippuryl-His-Leu
Lys-Ala-Phe-Arg
-
ACE inhibitory peptide derived from Arachis hypogaea protein hydrolysate using digestion by Alcalase, mass spectrometric sequence determination, overview. IC50 value is 0.085 mg/ml
Lys-Asp-Tyr-Arg-Leu
-
-
Lys-Leu-Pro-Arg-Gly-Thr-Leu-Phe
-
-
malonate
-
-
melanoidin
-
melanoidins obtained from coffee (three roasting degrees), beer, and sweet-wine show in-vitro angiotensin-converting enzyme-inhibitory activity. The activity in coffee melanoidinsis significantly higher at more severe heating conditions
-
Met-Arg-Trp
-
-
Met-Arg-Trp-Arg-Asp
-
-
Met-Trp
-
IC50: 0.0098 mM, non-competitive
methyl rosmarinate
-
0.01 mg/ml, 39.5% inhibition
MLGQTPT
-
-
MLN-4760
-
conversion of Ang II to Ang(1-7) is blocked by MLN-4760 but not by DX600
Monascus-fermented soybean extract
-
butanol, ethyl acetate, 50% ethanol-soluble extract and water-soluble extract
-
monomethyl phosphate
-
-
mugineic acid
-
IC50: 0.00028 mM
muracein A
muracein B
muracein C
MYPGIA
-
-
N-(3-{[(1R)-1-{[(benzyloxy)carbonyl]amino}-2-phenylethyl](hydroxy)phosphoryl}-2-{[3-(biphenyl-4-yl)-4,5-dihydro-1,2-oxazol-5-yl]methyl}propanoyl)-L-tryptophan
-
-
N-alpha-[1-(S)-carboxy-3-phenylpropyl]-L-Lys-L-Pro
-
-
N-bromosuccinimide
-
2 mM, 99.8% inhibition
N-[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl-L-proline
N-[(2S)-3-methyl-2-sulfanylpentanoyl]-2-phenoxy-L-phenylalanine
-
;
N-[(2S)-3-methyl-2-sulfanylpentanoyl]-3-phenoxy-L-phenylalanine
-
;
N-[(2S)-3-methyl-2-sulfanylpentanoyl]-O-phenyl-L-tyrosine
-
;
N-[(2S)-3-methyl-2-sulfanylpentanoyl]-O-[4-(trifluoromethyl)benzyl]-L-tyrosine
-
;
N-[(5S)-4-oxo-6-phenyl-5-[(phenylcarbonyl)amino]hexanoyl]-L-phenylalanine
-
N-[(5S)-4-oxo-6-phenyl-5-[(phenylcarbonyl)amino]hexanoyl]-L-tryptophan
-
N-[(5S)-5-[(tert-butoxycarbonyl)amino]-4-oxo-6-phenylhexanoyl]-L-phenylalanine
-
N-[(5S)-5-[(tert-butoxycarbonyl)amino]-4-oxo-6-phenylhexanoyl]-L-tryptophan
-
N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl-L-proline
-
i.e. MK 421. Effect of the inhibitor on the components of the renin system in healthy subjects : the drug has a prolonged duration of action and effectively reduces plasma converting enzyme activity, angiotensin II and aldosterone levels and thereby increases sodium diuresis
N-[(S)-1-Carboxy-3-phenylpropyl]-L-Ala-L-Pro
N-[1(S)-carboxy-5-aminopentyl]glycylglycine
-
weak competitive
N-[3-{[(1R)-1-{[(benzyloxy)carbonyl]amino}-2-phenylethyl](hydroxy)phosphoryl}-2-(biphenyl-4-ylmethyl)propanoyl]-L-tryptophan
-
-
N-{(2R)-3-{[(1R)-1-{[(benzyloxy)carbonyl]amino}-2-phenylethyl](hydroxy)phosphoryl}-2-[(3-phenyl-1,2-oxazol-5-yl)methyl]propanoyl}-L-tyrosine
-
-
N-{(2S)-3-{[(1R)-1-{[(benzyloxy)carbonyl]amino}-2-phenylethyl](hydroxy)phosphoryl}-2-[(3-phenyl-1,2-oxazol-5-yl)methyl]propanoyl}-L-tryptophan
-
-
N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline
-
effect of the inhibitor on the components of the renin system in healthy subjects : the drug has a prolonged duration of action and effectively reduces plasma converting enzyme activity, angiotensin II and aldosterone levels and thereby increases sodium diuresis
neutrase
-
about 70% ACE inhibitory
-
nicotianamine
NIPPLTQTPV
-
-
nitrate
-
-
O-(2,4-difluorobenzyl)-N-[(2S)-3-methyl-2-sulfanylpentanoyl]-L-tyrosine
-
;
O-(3,4-difluorobenzyl)-N-[(2S)-3-methyl-2-sulfanylpentanoyl]-L-tyrosine
-
;
O-(4-fluorobenzyl)-N-[(2S)-3-methyl-2-sulfanylpentanoyl]-L-tyrosine
-
;
O-benzyl-N-[(2S)-3-methyl-2-sulfanylpentanoyl]-L-tyrosine
-
;
O-[3,5-bis(trifluoromethyl)benzyl]-N-[(2S)-3-methyl-2-sulfanylpentanoyl]-L-tyrosine
;
oenothein B
-
IC50: 0.25 mM
omapatrilat
-
-
omega-phenylalkylcarboxylates
-
-
-
oxalate
-
-
p-aminocinnamate
-
-
PARPTSPP
-
-
peimisine
Pepsin
peptide
-
more angiotensin I converting enzyme-inhibitory peptides are present in hydrolyzed wet-milled corn germ compared to hydrolyzed dry-milled germ
Peptide inhibitors
-